Liraglutide and semaglutide reduce cardiovascular events in patients with type 2 diabetes and peripheral arterial disease

被引：0
|
作者：
Verma, S. [1 ,2 ]
Rasmussen, S. [3 ]
Saevereid, H. A. [3 ]
Ripa, M. Sejersten [3 ]
机构：
[1] St Michaels Hosp, Toronto, ON, Canada
[2] Univ Toronto, Toronto, ON, Canada
[3] Novo Nordisk AS, Soborg, Denmark
来源：
DIABETOLOGIA | 2020年 / 63卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
590
引用
收藏
页码：S283 / S284
页数：2
相关论文
共 50 条
  • [1] Liraglutide and Semaglutide Reduce Cardiovascular Events in Patients With Type 2 Diabetes and Peripheral Arterial Disease
    Verma, Subodh
    Rasmussen, Soren
    Saevereid, Hans Askelund
    Ripa, Maria Sejersten
    [J]. CIRCULATION, 2019, 140
  • [2] Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease
    Verma, Subodh
    Al-Omran, Mohammed
    Leiter, Lawrence A.
    Mazer, C. David
    Rasmussen, Soren
    Saevereid, Hans A.
    Ripa, Maria Sejersten
    Bonaca, Marc P.
    [J]. DIABETES OBESITY & METABOLISM, 2022, 24 (07): : 1288 - 1299
  • [3] Semaglutide Provides More Value for Money Than Dulaglutide or Liraglutide for Prevention of Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease
    Azuri, Joseph
    Aboalhasan, Enis
    Hammerman, Ariel
    Arbel, Ronen
    [J]. CIRCULATION, 2020, 142
  • [4] Effects of liraglutide on cardiovascular events in patients with type 2 diabetes and polyvascular disease: results of the LEADER trial
    Zinman, B.
    Verma, S.
    Bhatt, D. L.
    Bain, S. C.
    Mann, J.
    Nauck, M. A.
    Pratley, R. E.
    Michelsen, M. M.
    Fries, T. Monk
    Rasmussen, S.
    Leiter, L. A.
    [J]. DIABETOLOGIA, 2018, 61 : S555 - S556
  • [5] Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes
    Mehler, PS
    Coll, JR
    Estacio, R
    Esler, A
    Schrier, RW
    Hiatt, WR
    [J]. CIRCULATION, 2002, 106 (19) : 434 - 434
  • [6] Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes
    Mehler, PS
    Coll, JR
    Estacio, R
    Esler, A
    Schrier, RW
    Hiatt, WR
    [J]. CIRCULATION, 2003, 107 (05) : 753 - 756
  • [7] Peripheral arterial disease in patients with type 2 diabetes
    Eshcol, Jayasheel
    Jebarani, Saravanan
    Anjana, Ranjit Mohan
    Mohan, Viswanathan
    Pradeepa, Rajendra
    [J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2014, 28 (06) : 913 - 913
  • [8] Cardiovascular Risk of Semaglutide in Patients With Type 2 Diabetes
    Marso
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (02) : 159 - 159
  • [9] Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Cosmi, Franco
    Latini, Roberto
    Nicolucci, Antonio
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (09): : 890 - 890
  • [10] Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Marso, Steven P.
    Bain, Stephen C.
    Consoli, Agostino
    Eliaschewitz, Freddy G.
    Jodar, Esteban
    Leiter, Lawrence A.
    Lingvay, Ildiko
    Rosenstock, Julio
    Seufert, Jochen
    Warren, Mark L.
    Woo, Vincent
    Hansen, Oluf
    Holst, Anders G.
    Pettersson, Jonas
    Vilsboll, Tina
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19): : 1834 - 1844
12345